Biggest News Aggregation in the World
📰 Equal Life News

Equal Life News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Equal Life. Real-time updates on events, politics, business and more.

Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause

First-in-class treatment option reduces number and intensity of hot flashes and night sweats  TOKYO, Dec. 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. today announced the European Commission on...
United States Przegl Menopauzalny Naoki Okamura Rossella Nappi Committee For Medicinal Products Human Use J Public Health

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms due to menopause and patient-reported sleep disturbance at 24 weeks Women considered unsuitable included those with contraindications, who are averse to taking, have stopped taking or have conditions that suggest caution in using hormone therapy Results will support health technology a...
Noord Holland Rossella Nappi Naoki Okamura San Matteo Foundation University Of Pavia European Society Of Gynecology

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

 VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause TOKYO, May 12, 2023 /PRNewswire/ -- Astellas Pharma Inc. today... | June 14, 2023
United States Genevieve Neal Perry Naoki Okamura Astellas Pharma Prnewswire Astellas Pharma Inc Health Qual Life Outcomes

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science